Cover Image
Market Research Report
Product code 
1086112

Companion Diagnostic Market, by Application, by Technology (Real Time-Polymerase Chain Reaction, Gene Sequencing, Fluorescence in situ Hybridization, and Others), and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published: | Coherent Market Insights | 191 Pages | Delivery time: 2-3 business days

Price

Back to Top
Companion Diagnostic Market, by Application, by Technology (Real Time-Polymerase Chain Reaction, Gene Sequencing, Fluorescence in situ Hybridization, and Others), and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Published: May 11, 2022
Coherent Market Insights
Content info: 191 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Companion diagnostic is a diagnostic tool used by healthcare professionals to determine whether a particular therapeutic product is the suitability for the patient to outweigh any potential side effects of the therapeutic product. Companion diagnostic is advancing the course of patient care in the field of oncology sue to proper evaluation of therapeutic product and its efficiency towards the cancer patients. All the patients suffering from cancer are not able to be treated with immunotherapy. In such cases, companion diagnostics play an important role in helping physicians to identify the efficient targeted therapy for such cancer patients.

Market Dynamics

Robust product pipeline, increasing approval of companion diagnostic procedures, and high outsourcing of funds by companies for the development of companion diagnostic are the factors driving the global companion diagnostic market growth. For instance, in March 2021, F. Hoffmann-La Roche Ltd received the U.S. Food and Drug Administration (FDA) approval for the VENTANA PD-L1 (SP142) Assay, which is the first companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patient eligible for treatment with the Roche cancer immunotherapy Tecentriq (atezolizumab) plus chemotherapy.

Moreover, increasing incidence of cancer globally is also driving growth of the global companion diagnostic market. For instance, in September 2018, according to the Globocan 2018 report, Europe held the second position in new cancer cases and accounted for 23% and around 3,911,317 new cases of cancer.

Increasing investment in the research and development by pharmaceutical and biotechnological companies targeting major chronic diseases such as cancer, cardiovascular disease, neurological disease, and respiratory disease is expected to drive the companion diagnostic market growth over the forecast period. For instance, in 2018, Abbott Molecular, Inc received approval from the U.S. Food Drug and Administration for Abbott real time IDHI, an in vitro polymerase chain reaction assay for detection of IDHI R123 mutations for identifying acute myeloid leukemia with treatment therapy of TIBSOVO.

Key features of the study:

  • This report provides in-depth analysis of the global companion diagnostic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global companion diagnostic market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Agilent Technologies, Inc, QIAGEN N.V, Abbott Laboratories, Inc., Almac Group, Danaher Corporation, Illumina, Inc, bioMerieux SA, Myriad Genetics, Inc, Sysmex Corporation, Thermo Fisher Scientific Inc, Abnova Corporation, Guardant Health, Inc., Icon Plc, and Biogenex Laboratories, Inc
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global companion diagnostic market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global companion diagnostic market

Detailed Segmentation:

  • Global Companion Diagnostic Market, By Application :
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • Melanoma
    • Others
  • Global Companion Market, By Technology :
    • Real Time- Polymerase Chain Reactions (PCR)
    • Gene Sequencing
    • Fluorescence in-situ Hybridization
    • Others
  • Global Companion Diagnostic Market , By Region:
    • North America
      • By Application:
      • Lung Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gastric Cancer
      • Others
      • Others
      • By Technology :
      • Real Time Polymerase Chain Reaction (PCR)
      • Generation Sequencing
      • Fluorescence in- situ Hybridization
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Application:
      • Lung Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gastric Cancer
      • Others
      • Others
      • By Technology :
      • Real Time Polymerase Chain Reaction (PCR)
      • Generation Sequencing
      • Fluorescence in- situ Hybridization
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Application:
      • Lung Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gastric Cancer
      • Others
      • Others
      • By Technology :
      • Real Time Polymerase Chain Reaction (PCR)
      • Generation Sequencing
      • Fluorescence in- situ Hybridization
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Application:
      • Lung Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gastric Cancer
      • Others
      • Others
      • By Technology :
      • Real Time Polymerase Chain Reaction (PCR)
      • Generation Sequencing
      • Fluorescence in- situ Hybridization
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Application:
      • Lung Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gastric Cancer
      • Others
      • Others
      • By Technology :
      • Real Time Polymerase Chain Reaction (PCR)
      • Generation Sequencing
      • Fluorescence in- situ Hybridization
      • Others
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Application:
      • Lung Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gastric Cancer
      • Others
      • Others
      • By Technology :
      • Real Time Polymerase Chain Reaction (PCR)
      • Generation Sequencing
      • Fluorescence in- situ Hybridization
      • Others
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Hoffmann-La Roche AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Agilent Technologies, Inc,
    • QIAGEN N.V,
    • Abbott Laboratories, Inc.
    • Almac Group
    • Danaher Corporation
    • Illumina, Inc.
    • bioMerieux SA
    • Myriad Genetics, Inc
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc
    • Abnova Corporation
    • Guardant Health, Inc
    • Icon Plc
    • Biogenex Laboratories, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI109

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Application
    • Market Snippet, By Technology
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Impact Analysis
  • Market Opportunities
  • New Product Launches
  • Mergers and Acquisitions
  • Regulatory Scenario
  • Pest Analysis
  • Porters Five Forces Model

4. Global Companion Diagnostic Market, Impact of COVID-19 Pandemic

  • Post COVID-19 Impact
  • Implementation diagnosis/testing guidelines
  • Implementation of Testing Guidelines in Case of Companion Diagnostics

5. Global Companion Diagnostic Market, By Application, 2017-2028 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017-2027
    • Segment Trends
    • Lung Cancer
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2022-2028, (US$ Mn)
    • Breast Cancer
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2022-2028, (US$ Mn)
    • Colorectal Cancer
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2022-2028, (US$ Mn)
    • Gastric Cancer
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2022-2028, (US$ Mn)
    • Melanoma
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2022-2028, (US$ Mn)
    • Others
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2022-2028, (US$ Mn)
    • Cardiovascular Disease
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2022-2028, (US$ Mn)
    • Neurological Disease
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2022-2028, (US$ Mn)
    • Others
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2022-2028, (US$ Mn)

6. Global Companion Diagnostic Market, By Technology, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017- 2027
    • Segment Trends
    • Real Time -Polymerase Chain Reaction ( PVR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
    • Gene Sequencing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
    • Fluorescence in- situ Hybridization
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)

7. Global Companion Diagnostic Market, By Region, 2017-2028 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Country, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Countries, 2017-2027
  • North America
    • Introduction
    • Market Size and Forecast, By Application, 2020-2027 (US$ Mn)
    • Market Size and Forecast, By Technology, 2022-2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Application, 2020-2027 (US$ Mn)
    • Market Size and Forecast, By Technology, 2022-2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Application, 2020-2027 (US$ Mn)
    • Market Size and Forecast, By Technology, 2022-2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Application, 2020-2027 (US$ Mn)
    • Market Size and Forecast, By Technology, 2022-2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Application, 2020-2027 (US$ Mn)
    • Market Size and Forecast, By Technology, 2022-2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Application, 2020-2027 (US$ Mn)
    • Market Size and Forecast, By Technology, 2022-2028 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2020-2027 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Company Profiles
    • F. Hoffmann-La Roche AG *
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Agilent Technologies, Inc.
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • QIAGEN N.V
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Abbott Laboratories, Inc
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Almac Group
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Danaher Corporation
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Illumina, Inc
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • bioMerieux SA
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Myriad Genetics, Inc
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sysmex Corporation
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Thermo Fisher Scientific Inc
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Abnova Corporation
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Guardant Health, Inc.
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Icon Plc
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Biogenex Laboratories, Inc
    • Company Overview
    • Clinical Trial Phase Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies